ScoreWhy is Shanghai MicuRx Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of 29.42% and Operating profit at -1.97% over the last 5 years
3
Flat results in Sep 25
- ROCE(HY) Lowest at -83.12%
- DEBT-EQUITY RATIO (HY) Highest at -46.16 %
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -1.53%, its profits have risen by 25%
5
Below par performance in long term as well as near term
- Along with generating -1.53% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Shanghai MicuRx Pharmaceutical Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Shanghai MicuRx Pharmaceutical Co., Ltd.
-25.86%
0.82
50.86%
China Shanghai Composite
18.93%
1.58
14.20%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
43.46%
EBIT Growth (5y)
10.07%
EBIT to Interest (avg)
-53.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.81
Sales to Capital Employed (avg)
0.19
Tax Ratio
1.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.47
EV to EBIT
-6.94
EV to EBITDA
-7.43
EV to Capital Employed
21.71
EV to Sales
9.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-312.98%
ROE (Latest)
-114.30%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend22What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY -183.54 MM
NET SALES(Q)
Highest at CNY 42.06 MM
RAW MATERIAL COST(Y)
Fallen by -21.12% (YoY
OPERATING PROFIT(Q)
Highest at CNY -19.61 MM
OPERATING PROFIT MARGIN(Q)
Highest at -46.63 %
PRE-TAX PROFIT(Q)
Highest at CNY -22.93 MM
NET PROFIT(Q)
Highest at CNY -22.95 MM
EPS(Q)
Highest at CNY -0.03
-15What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at -27.42 %
DEBTORS TURNOVER RATIO(HY)
Lowest at 2.55 times
INVENTORY TURNOVER RATIO(HY)
Lowest at 0.47 times
INTEREST(Q)
Highest at CNY 4.26 MM
Here's what is working for Shanghai MicuRx Pharmaceutical Co., Ltd.
Net Sales
Highest at CNY 42.06 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (CNY MM)
Operating Cash Flow
Highest at CNY -183.54 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Net Sales
At CNY 42.06 MM has Grown at 26.62%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Operating Profit
Highest at CNY -19.61 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit Margin
Highest at -46.63 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CNY -22.93 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Pre-Tax Profit
At CNY -22.93 MM has Grown at 63.66%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Highest at CNY -22.95 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
Net Profit
At CNY -22.95 MM has Grown at 63.62%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY -0.03
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Raw Material Cost
Fallen by -21.12% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Shanghai MicuRx Pharmaceutical Co., Ltd.
Interest
At CNY 4.26 MM has Grown at 27.13%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Debt-Equity Ratio
Highest at -27.42 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Debtors Turnover Ratio
Lowest at 2.55 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Interest
Highest at CNY 4.26 MM
in the last five periods and Increased by 27.13% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Inventory Turnover Ratio
Lowest at 0.47 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
